Tagged with Specialty Pharma

Spain Accord’s Marc Comas highlights the company’s presence in Spain with leading oncology products, three biosimilars and investment in specialty pharma. He shares his views on the COVID pandemic, the future of the supply chain, the importance of Spain, Barcelona’s attractiveness for the pharma industry, and explains why Accord will be…

Spain Way before securing the CEO role at Esteve in 2018, Staffan Schüberg built a career that saw him rise through the ranks of Lundbeck, from commercial activities in Sweden to global chief commercial officer.   Schüberg got his first pharma job at Lundbeck in 1994 after serving in the Swedish…

Spain Esteve’s CEO outlines the transformation journey of the Spanish company after taking over in 2018, commenting on how the divestment of its generics business has helped the company lay the foundation of a specialty pharma player in CNS, oncology and ophthalmology. Staffan Schüberg, former EVP and Chief Commercial Officer at…

Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a specialty pharma player focused on the digestive system, has overseen a number of acquisitions and the growth of the company from 30 to 300 employees. Here, he shares his insights on why M&A may be a better strategy…

Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a Switzerland-based specialty pharma player focused on the digestive system, shares his M&A principles and insights, their exciting recent acquisition of DIFICLIR™ from Astellas, and the company’s recognition as a Great Place to Work® (GPTW) in Switzerland.   For…

UAE Myriam Hakim, the recently appointed GM for Japanese specialty pharma firm Kyowa Kirin’s UAE affiliate, discusses the strategic significance of the UAE and the Gulf region as a whole to the global group.   I appreciate all the efforts the [UAE] authorities have been putting into fast-tracking registration for innovative…

Sweden Karo Pharma is a Swedish specialty pharma company that develops and markets products to pharmacies and healthcare providers. CEO Christoffer Lorenzen discusses the company’s growth strategy through acquisitions of trusted well-positioned brands, the challenge of incorporating two similar-sized companies, and his high ambitions for the future of Karo Pharma.  …

China Tony Au, general manager of AbbVie China, shares the key milestones for the affiliate in the past six years, the strong foundation he has built for AbbVie in China, the mission of AbbVie to be the most reliable pharmaceutical company in China, and the exciting pipeline of innovative products and…

Spain Sergio Serra Ripol, managing director of Tillotts Pharma Spain, highlights the challenges associated with setting up the affiliate and the strategic importance of Spain as Tillotts grows its European footprint. Furthermore, he gives an insight into the importance of relationships in building the company’s network and his vision for the…

UK Ben Ellis, general manager at Lupin UK and Ireland, talks about the strategic challenges of transitioning from the sphere of generics to specialist pharma and how he hopes Lupin can change how it is perceived. Furthermore, he comments on the uncertainty Brexit brings to the industry and how healthcare should…

Canada Still in the process of integration, Mallinckrodt is preparing to build its launch structure in Canada. With several innovative products in the pipeline, Robin Hunter, general manager of Canadian operations, highlights the company’s ambition to be a top tier innovative specialty pharma company with a specific area of focus in…

Switzerland Lupin’s EMEA President Thierry Volle explains that to fuel growth in the EMEA region, Lupin is investing heavily in transforming the business from a generics company into a specialty pharma player. Mr Volle, given your background in the innovative pharma sector, what was it that attracted you to join Lupin?…